Combination Chemotx in Treating Children or Adolescents With Newly Diagnosed Stg III or Stg IV Lymphoblastic Lymphoma

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborator:
Information provided by (Responsible Party):
Children's Oncology Group
ClinicalTrials.gov Identifier:
NCT00004228
First received: January 28, 2000
Last updated: October 8, 2013
Last verified: October 2013
  Purpose

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. It is not yet known which regimen of combination chemotherapy is most effective for lymphoblastic lymphoma.

PURPOSE: This randomized phase III trial is studying different regimens of combination chemotherapy to compare how well they work in treating children or adolescents with newly diagnosed stage III or stage IV lymphoblastic lymphoma.


Condition Intervention Phase
Lymphoma
Drug: asparaginase
Drug: cyclophosphamide
Drug: cytarabine
Drug: daunorubicin hydrochloride
Drug: dexamethasone
Drug: doxorubicin hydrochloride
Drug: leucovorin calcium
Drug: mercaptopurine
Drug: methotrexate
Drug: prednisone
Drug: thioguanine
Drug: vincristine sulfate
Radiation: radiation therapy
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Randomized Phase III Study for the Treatment of Newly Diagnosed Disseminated Lymphoblastic Lymphoma or Localized Lymphoblastic Lymphoma

Resource links provided by NLM:


Further study details as provided by Children's Oncology Group:

Primary Outcome Measures:
  • Event-free Survival [ Time Frame: 5 years ] [ Designated as safety issue: No ]
    Assessed by time to treatment failure, occurrence of second malignant neoplasm, or death from any cause. Statistical analysis will be to estimate the difference in the proportion of patients treated with each therapy who are long-term event-free survivors due either to the difference between the backbone therapy regimens (CCG BFM vs NHL/BFM-95), or due to the intensification.


Secondary Outcome Measures:
  • Survival as Assessed by Time to Death [ Time Frame: 5 years ] [ Designated as safety issue: No ]

Enrollment: 393
Study Start Date: June 2000
Primary Completion Date: August 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: A0 (localized disease Stg I/II) Modified CCG BFM
Phase I - 5 week induction (Vincristine Sulfate, daunorubicin hydrochloride, L-Asparaginase, Intrathecal Cytarabine, Intrathecal Methotrexate, Prednisone). Phase II - 5 week consolidation (Mercaptopurine, Cyclophosphamide, Cytarabine, Intrathecal Methotrexate, Prednisone). Phase III - 8 week Interim Maintenance (Mercaptopurine, Methotrexate, Intrathecal Methotrexate). Phase IV - 7 week Delayed Intensification (Vincristine Sulfate, Doxorubicin, L-Asparaginase, Dexamethasone, Cyclophosphamide, Thioguanine, Cytarabine, Intrathecal Methotrexate). Phase V - 12 week courses (Vincristine Sulfate, Prednisone, Methotrexate, Intrathecal Methotrexate)
Drug: asparaginase
Given IV
Other Names:
  • E.coli L-asparaginase
  • EC 3.5.2.2
  • colaspase
  • L-asnase
  • Elspar
  • Kidrolase
  • Crasnitin
  • Leunase
  • NSC#109229
Drug: cyclophosphamide
Given IV
Other Names:
  • Cytoxan
  • NSC #26271
Drug: cytarabine
Given IV
Other Names:
  • cytosine arabinoside
  • Ara-C
  • Cytosar
  • NSC #63878
Drug: daunorubicin hydrochloride
Given IV
Other Names:
  • daunomycin
  • rubidomycin
  • Cerubidine
  • NSC #82151
Drug: dexamethasone
Given IV
Other Names:
  • Decadron
  • Hexadrol
  • Dexone
  • Dexameth
  • NSC #34521
Drug: doxorubicin hydrochloride
Given IV
Other Names:
  • Adriamycin
  • NSC #123127
Drug: mercaptopurine
Given IV
Other Names:
  • 6-MP
  • Purinethol
  • 6-mercaptopurine
  • NSC #000755
Drug: methotrexate
Given IV
Other Names:
  • MTX
  • amethopterin
  • Trexall
  • NSC #000740
Drug: prednisone
Given IV
Other Names:
  • Deltasone
  • Meticorten
  • Orasone
  • Liquid Pred
  • Pediapred
  • Sterapred
  • NSC #010023
Drug: thioguanine
Given PO
Other Names:
  • 6-thioguanine
  • 2-amino-1,7-dihydro-6H-purine-6-thione
  • WR-1141
  • Tabloid
  • Lanvis
  • NSC # 751
Drug: vincristine sulfate
Given IV
Other Names:
  • Oncovin
  • VCR
  • LCR
  • NSC #67574
Experimental: A1 (Disseminated, No CNS - CCG mod BFM w/out intens
Phase I - 5 week induction (Vincristine Sulfate, daunorubicin hydrochloride, L-Asparaginase, Intrathecal Cytarabine, Intrathecal Methotrexate, prednisone). Phase II - 5 week consolidation (Mercaptopurine, Cyclophosphamide, Cytarabine, Intrathecal Methotrexate, prednisone). Phase III - 8 week Interim Maintenance (Mercaptopurine, Methotrexate, Intrathecal Methotrexate). Phase IV - 7 week Delayed Intensification (Vincristine Sulfate, doxorubicin hydrochloride, L-Asparaginase, Dexamethasone, Cyclophosphamide, Thioguanine, Cytarabine, Intrathecal Methotrexate). Phase V - 12 week courses (Vincristine Sulfate, prednisone, Methotrexate, Intrathecal Methotrexate)
Drug: asparaginase
Given IV
Other Names:
  • E.coli L-asparaginase
  • EC 3.5.2.2
  • colaspase
  • L-asnase
  • Elspar
  • Kidrolase
  • Crasnitin
  • Leunase
  • NSC#109229
Drug: cyclophosphamide
Given IV
Other Names:
  • Cytoxan
  • NSC #26271
Drug: cytarabine
Given IV
Other Names:
  • cytosine arabinoside
  • Ara-C
  • Cytosar
  • NSC #63878
Drug: daunorubicin hydrochloride
Given IV
Other Names:
  • daunomycin
  • rubidomycin
  • Cerubidine
  • NSC #82151
Drug: dexamethasone
Given IV
Other Names:
  • Decadron
  • Hexadrol
  • Dexone
  • Dexameth
  • NSC #34521
Drug: doxorubicin hydrochloride
Given IV
Other Names:
  • Adriamycin
  • NSC #123127
Drug: mercaptopurine
Given IV
Other Names:
  • 6-MP
  • Purinethol
  • 6-mercaptopurine
  • NSC #000755
Drug: methotrexate
Given IV
Other Names:
  • MTX
  • amethopterin
  • Trexall
  • NSC #000740
Drug: prednisone
Given IV
Other Names:
  • Deltasone
  • Meticorten
  • Orasone
  • Liquid Pred
  • Pediapred
  • Sterapred
  • NSC #010023
Drug: thioguanine
Given PO
Other Names:
  • 6-thioguanine
  • 2-amino-1,7-dihydro-6H-purine-6-thione
  • WR-1141
  • Tabloid
  • Lanvis
  • NSC # 751
Drug: vincristine sulfate
Given IV
Other Names:
  • Oncovin
  • VCR
  • LCR
  • NSC #67574
Experimental: A2 (Disseminated, No CNS - CCG mod BFM w/out intens
Phase I - 5 week induction (Vincristine Sulfate, daunorubicin hydrochloride, Cyclophosphamide, L-Asparaginase, Intrathecal Cytarabine, Intrathecal Methotrexate, Prednisone). Phase II - 5 week consolidation (Mercaptopurine, Cyclophosphamide, Cytarabine, Intrathecal Methotrexate, Prednisone). Phase III - 8 week Interim Maintenance (Mercaptopurine, Methotrexate, Intrathecal Methotrexate). Phase IV - 7 week Delayed Intensification (Vincristine Sulfate, Cyclophosphamide, daunorubicin, L-Asparaginase, Dexamethasone, Cyclophosphamide, Thioguanine, Cytarabine, Intrathecal Methotrexate). Phase V - 12 week courses (Vincristine Sulfate, Prednisone, Mercaptopurine, Methotrexate, Intrathecal Methotrexate)
Drug: asparaginase
Given IV
Other Names:
  • E.coli L-asparaginase
  • EC 3.5.2.2
  • colaspase
  • L-asnase
  • Elspar
  • Kidrolase
  • Crasnitin
  • Leunase
  • NSC#109229
Drug: cyclophosphamide
Given IV
Other Names:
  • Cytoxan
  • NSC #26271
Drug: cytarabine
Given IV
Other Names:
  • cytosine arabinoside
  • Ara-C
  • Cytosar
  • NSC #63878
Drug: daunorubicin hydrochloride
Given IV
Other Names:
  • daunomycin
  • rubidomycin
  • Cerubidine
  • NSC #82151
Drug: dexamethasone
Given IV
Other Names:
  • Decadron
  • Hexadrol
  • Dexone
  • Dexameth
  • NSC #34521
Drug: doxorubicin hydrochloride
Given IV
Other Names:
  • Adriamycin
  • NSC #123127
Drug: mercaptopurine
Given IV
Other Names:
  • 6-MP
  • Purinethol
  • 6-mercaptopurine
  • NSC #000755
Drug: methotrexate
Given IV
Other Names:
  • MTX
  • amethopterin
  • Trexall
  • NSC #000740
Drug: prednisone
Given IV
Other Names:
  • Deltasone
  • Meticorten
  • Orasone
  • Liquid Pred
  • Pediapred
  • Sterapred
  • NSC #010023
Drug: thioguanine
Given PO
Other Names:
  • 6-thioguanine
  • 2-amino-1,7-dihydro-6H-purine-6-thione
  • WR-1141
  • Tabloid
  • Lanvis
  • NSC # 751
Drug: vincristine sulfate
Given IV
Other Names:
  • Oncovin
  • VCR
  • LCR
  • NSC #67574
Experimental: B2 (CNS+) NHL/BFM-95 w/intens delayed radiation therapy
Phase I - 5 week induction (Vincristine Sulfate, daunorubicin hydrochloride, Cyclophosphamide, L-Asparaginase, Intrathecal Cytarabine, Intrathecal Methotrexate, Prednisone). Phase II - 5 week consolidation (Mercaptopurine, Cyclophosphamide, Cytarabine, Intrathecal Methotrexate, Prednisone). Phase III - 8 week Interim Maintenance (Mercaptopurine, Methotrexate, Intrathecal Methotrexate, Leucovorin Calcium). Phase IV - 7 week Delayed Intensification (Vincristine Sulfate, Cyclophosphamide, daunorubicin, L-Asparaginase, Dexamethasone, Cyclophosphamide, Thioguanine, Cytarabine, Intrathecal Methotrexate). Phase V - 12 week courses (Vincristine Sulfate, Prednisone, Mercaptopurine, Methotrexate, Intrathecal Methotrexate)
Drug: asparaginase
Given IV
Other Names:
  • E.coli L-asparaginase
  • EC 3.5.2.2
  • colaspase
  • L-asnase
  • Elspar
  • Kidrolase
  • Crasnitin
  • Leunase
  • NSC#109229
Drug: cyclophosphamide
Given IV
Other Names:
  • Cytoxan
  • NSC #26271
Drug: cytarabine
Given IV
Other Names:
  • cytosine arabinoside
  • Ara-C
  • Cytosar
  • NSC #63878
Drug: daunorubicin hydrochloride
Given IV
Other Names:
  • daunomycin
  • rubidomycin
  • Cerubidine
  • NSC #82151
Drug: dexamethasone
Given IV
Other Names:
  • Decadron
  • Hexadrol
  • Dexone
  • Dexameth
  • NSC #34521
Drug: doxorubicin hydrochloride
Given IV
Other Names:
  • Adriamycin
  • NSC #123127
Drug: leucovorin calcium
Given IV
Other Names:
  • LCV
  • Wellcovorin
  • citrovorum factor
  • folinic acid
  • NSC #003590
Drug: mercaptopurine
Given IV
Other Names:
  • 6-MP
  • Purinethol
  • 6-mercaptopurine
  • NSC #000755
Drug: methotrexate
Given IV
Other Names:
  • MTX
  • amethopterin
  • Trexall
  • NSC #000740
Drug: prednisone
Given IV
Other Names:
  • Deltasone
  • Meticorten
  • Orasone
  • Liquid Pred
  • Pediapred
  • Sterapred
  • NSC #010023
Drug: thioguanine
Given PO
Other Names:
  • 6-thioguanine
  • 2-amino-1,7-dihydro-6H-purine-6-thione
  • WR-1141
  • Tabloid
  • Lanvis
  • NSC # 751
Drug: vincristine sulfate
Given IV
Other Names:
  • Oncovin
  • VCR
  • LCR
  • NSC #67574
Radiation: radiation therapy
Experimental: B1 (Disseminated CNS- <Amend 7B) NHL/BFM-95 w/out intens
Phase I - 5 week induction (Vincristine Sulfate, daunorubicin hydrochloride, Cyclophosphamide, L-Asparaginase, Intrathecal Cytarabine, Intrathecal Methotrexate, Prednisone). Phase II - 5 week consolidation (Mercaptopurine, Cyclophosphamide, Cytarabine, Intrathecal Methotrexate, Prednisone). Phase III - 8 week Interim Maintenance (Mercaptopurine, Methotrexate, Intrathecal Methotrexate, Leucovorin Calcium). Phase IV - 7 week Delayed Intensification (Vincristine Sulfate, Cyclophosphamide, daunorubicin, L-Asparaginase, Dexamethasone, Cyclophosphamide, Thioguanine, Cytarabine, Intrathecal Methotrexate). Phase V - 12 week courses (Vincristine Sulfate, Prednisone, Mercaptopurine, Methotrexate, Intrathecal Methotrexate)
Drug: asparaginase
Given IV
Other Names:
  • E.coli L-asparaginase
  • EC 3.5.2.2
  • colaspase
  • L-asnase
  • Elspar
  • Kidrolase
  • Crasnitin
  • Leunase
  • NSC#109229
Drug: cyclophosphamide
Given IV
Other Names:
  • Cytoxan
  • NSC #26271
Drug: cytarabine
Given IV
Other Names:
  • cytosine arabinoside
  • Ara-C
  • Cytosar
  • NSC #63878
Drug: daunorubicin hydrochloride
Given IV
Other Names:
  • daunomycin
  • rubidomycin
  • Cerubidine
  • NSC #82151
Drug: dexamethasone
Given IV
Other Names:
  • Decadron
  • Hexadrol
  • Dexone
  • Dexameth
  • NSC #34521
Drug: doxorubicin hydrochloride
Given IV
Other Names:
  • Adriamycin
  • NSC #123127
Drug: leucovorin calcium
Given IV
Other Names:
  • LCV
  • Wellcovorin
  • citrovorum factor
  • folinic acid
  • NSC #003590
Drug: mercaptopurine
Given IV
Other Names:
  • 6-MP
  • Purinethol
  • 6-mercaptopurine
  • NSC #000755
Drug: methotrexate
Given IV
Other Names:
  • MTX
  • amethopterin
  • Trexall
  • NSC #000740
Drug: prednisone
Given IV
Other Names:
  • Deltasone
  • Meticorten
  • Orasone
  • Liquid Pred
  • Pediapred
  • Sterapred
  • NSC #010023
Drug: thioguanine
Given PO
Other Names:
  • 6-thioguanine
  • 2-amino-1,7-dihydro-6H-purine-6-thione
  • WR-1141
  • Tabloid
  • Lanvis
  • NSC # 751
Drug: vincristine sulfate
Given IV
Other Names:
  • Oncovin
  • VCR
  • LCR
  • NSC #67574
Experimental: B2 (Disseminated,CNS- (< Amend 7B)) NHL/BFM-95 w/intens
Phase I - 5 week induction (Vincristine Sulfate, daunorubicin hydrochloride, Cyclophosphamide, L-Asparaginase, Intrathecal Cytarabine, Intrathecal Methotrexate, Prednisone). Phase II - 5 week consolidation (Mercaptopurine, Cyclophosphamide, Cytarabine, Intrathecal Methotrexate, Prednisone). Phase III - 8 week Interim Maintenance (Mercaptopurine, Methotrexate, Intrathecal Methotrexate, Leucovorin Calcium). Phase IV - 7 week Delayed Intensification (Vincristine Sulfate, Cyclophosphamide, daunorubicin, L-Asparaginase, Dexamethasone, Cyclophosphamide, Thioguanine, Cytarabine, Intrathecal Methotrexate). Phase V - 12 week courses (Vincristine Sulfate, Prednisone, Mercaptopurine, Methotrexate, Intrathecal Methotrexate)
Drug: asparaginase
Given IV
Other Names:
  • E.coli L-asparaginase
  • EC 3.5.2.2
  • colaspase
  • L-asnase
  • Elspar
  • Kidrolase
  • Crasnitin
  • Leunase
  • NSC#109229
Drug: cyclophosphamide
Given IV
Other Names:
  • Cytoxan
  • NSC #26271
Drug: cytarabine
Given IV
Other Names:
  • cytosine arabinoside
  • Ara-C
  • Cytosar
  • NSC #63878
Drug: daunorubicin hydrochloride
Given IV
Other Names:
  • daunomycin
  • rubidomycin
  • Cerubidine
  • NSC #82151
Drug: dexamethasone
Given IV
Other Names:
  • Decadron
  • Hexadrol
  • Dexone
  • Dexameth
  • NSC #34521
Drug: doxorubicin hydrochloride
Given IV
Other Names:
  • Adriamycin
  • NSC #123127
Drug: leucovorin calcium
Given IV
Other Names:
  • LCV
  • Wellcovorin
  • citrovorum factor
  • folinic acid
  • NSC #003590
Drug: mercaptopurine
Given IV
Other Names:
  • 6-MP
  • Purinethol
  • 6-mercaptopurine
  • NSC #000755
Drug: methotrexate
Given IV
Other Names:
  • MTX
  • amethopterin
  • Trexall
  • NSC #000740
Drug: prednisone
Given IV
Other Names:
  • Deltasone
  • Meticorten
  • Orasone
  • Liquid Pred
  • Pediapred
  • Sterapred
  • NSC #010023
Drug: thioguanine
Given PO
Other Names:
  • 6-thioguanine
  • 2-amino-1,7-dihydro-6H-purine-6-thione
  • WR-1141
  • Tabloid
  • Lanvis
  • NSC # 751
Drug: vincristine sulfate
Given IV
Other Names:
  • Oncovin
  • VCR
  • LCR
  • NSC #67574
Experimental: B1 (Disseminated CNS-) NHL/BFM-95 w/out intens
Phase I - 5 week induction (Vincristine Sulfate, daunorubicin hydrochloride, Cyclophosphamide, L-Asparaginase, Intrathecal Cytarabine, Intrathecal Methotrexate, Prednisone). Phase II - 5 week consolidation (Mercaptopurine, Cyclophosphamide, Cytarabine, Intrathecal Methotrexate, Prednisone). Phase III - 8 week Interim Maintenance (Mercaptopurine, Methotrexate, Intrathecal Methotrexate, Leucovorin Calcium). Phase IV - 7 week Delayed Intensification (Vincristine Sulfate, Cyclophosphamide, daunorubicin, L-Asparaginase, Dexamethasone, Cyclophosphamide, Thioguanine, Cytarabine, Intrathecal Methotrexate). Phase V - 12 week courses (Vincristine Sulfate, Prednisone, Mercaptopurine, Methotrexate, Intrathecal Methotrexate)
Drug: asparaginase
Given IV
Other Names:
  • E.coli L-asparaginase
  • EC 3.5.2.2
  • colaspase
  • L-asnase
  • Elspar
  • Kidrolase
  • Crasnitin
  • Leunase
  • NSC#109229
Drug: cyclophosphamide
Given IV
Other Names:
  • Cytoxan
  • NSC #26271
Drug: cytarabine
Given IV
Other Names:
  • cytosine arabinoside
  • Ara-C
  • Cytosar
  • NSC #63878
Drug: daunorubicin hydrochloride
Given IV
Other Names:
  • daunomycin
  • rubidomycin
  • Cerubidine
  • NSC #82151
Drug: dexamethasone
Given IV
Other Names:
  • Decadron
  • Hexadrol
  • Dexone
  • Dexameth
  • NSC #34521
Drug: doxorubicin hydrochloride
Given IV
Other Names:
  • Adriamycin
  • NSC #123127
Drug: leucovorin calcium
Given IV
Other Names:
  • LCV
  • Wellcovorin
  • citrovorum factor
  • folinic acid
  • NSC #003590
Drug: mercaptopurine
Given IV
Other Names:
  • 6-MP
  • Purinethol
  • 6-mercaptopurine
  • NSC #000755
Drug: methotrexate
Given IV
Other Names:
  • MTX
  • amethopterin
  • Trexall
  • NSC #000740
Drug: prednisone
Given IV
Other Names:
  • Deltasone
  • Meticorten
  • Orasone
  • Liquid Pred
  • Pediapred
  • Sterapred
  • NSC #010023
Drug: thioguanine
Given PO
Other Names:
  • 6-thioguanine
  • 2-amino-1,7-dihydro-6H-purine-6-thione
  • WR-1141
  • Tabloid
  • Lanvis
  • NSC # 751
Drug: vincristine sulfate
Given IV
Other Names:
  • Oncovin
  • VCR
  • LCR
  • NSC #67574

  Show Detailed Description

  Eligibility

Ages Eligible for Study:   1 Year to 30 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

DISEASE CHARACTERISTICS:

  • Newly diagnosed disseminated lymphoblastic lymphoma or localized lymphoblastic lymphoma*

    • Less than 25% tumor cells in the bone marrow
    • Previously untreated (prior intrathecal cytarabine allowed if protocol therapy begins within 72 hours)
    • Stage III or IV disease
  • NOTE: *Localized lymphoblastic lymphoma is closed to accrual as of 10/2005

PATIENT CHARACTERISTICS:

Age:

  • 1 to 30

Performance status:

  • Not specified

Life expectancy:

  • Not specified

Hematopoietic:

  • Not specified

Hepatic:

  • Not specified

Renal:

  • Not specified

Cardiovascular:

  • Adequate cardiac function

PRIOR CONCURRENT THERAPY:

Biologic therapy:

  • Not specified

Chemotherapy:

  • See Disease Characteristics

Endocrine therapy:

  • Emergency steroid therapy (if required) must be started within 72 hours prior to protocol therapy

Radiotherapy:

  • Emergency radiotherapy (if required) must be started within 72 hours prior to protocol therapy

Surgery:

  • Not specified

Other:

  • No other prior therapy except for emergency treatment of airway obstruction and/or superior vena cava syndrome
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00004228

  Show 176 Study Locations
Sponsors and Collaborators
Children's Oncology Group
Investigators
Study Chair: Minnie Abromowitch, MD Children's Hospital Medical Center, Cincinnati
  More Information

Additional Information:
Publications:
Abromowitch M, Termuhlen A, Chang M, et al.: High-dose methotrexate and early intensification of therapy do not improve 3 year EFS in children and adolescents with disseminated lymphoblastic lymphoma: results of the randomized arms of COG A5971. [Abstract] Blood 112 (11): A-3610, 2008.
Coustan-Smith E, Abromowitz M, Sandlund JT, et al.: A novel approach for minimal residual disease detection in childhood T-cell lymphoblastic lymphoma (T-LL): a Children's Oncology Group report. [Abstract] Blood 110 (11): A-3564, 2007.

Responsible Party: Children's Oncology Group
ClinicalTrials.gov Identifier: NCT00004228     History of Changes
Other Study ID Numbers: A5971, CCG-59701, CCG-59701C, CCG-A5971, POG-A5971, CDR0000067470
Study First Received: January 28, 2000
Results First Received: October 8, 2013
Last Updated: October 8, 2013
Health Authority: United States: Food and Drug Administration

Keywords provided by Children's Oncology Group:
stage III childhood lymphoblastic lymphoma
stage IV childhood lymphoblastic lymphoma

Additional relevant MeSH terms:
Lymphoma
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Lymphoma, Non-Hodgkin
Neoplasms by Histologic Type
Neoplasms
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Leukemia, Lymphoid
Leukemia
6-Mercaptopurine
Cytarabine
Methotrexate
Thioguanine
Cyclophosphamide
Asparaginase
Daunorubicin
Dexamethasone
Doxorubicin
Prednisone
Vincristine
BB 1101
Dexamethasone acetate
Dexamethasone 21-phosphate
Leucovorin
Levoleucovorin
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions

ClinicalTrials.gov processed this record on July 22, 2014